In the autologous settings, instead, T cell products can be generated by the expansion of tumor-reactive cells isolated from tumor specimens (TILs) or by the genetic engineering of peripheral blood T cells with TCR or CAR, an antibody-derived single-chain variable fragment fused to T cell signaling domain(s), specific for tumor-specific/associated Ags (46, 85, 86). Here, JAG1 is linked to neoplasm.